Michael Brosnan - Fresenius Medical CFO
FMCQF Stock | USD 36.95 0.00 0.00% |
CFO
Mr. Michael Brosnan resigned as Chief Financial Officer and Member of the Management Board at Fresenius Medical Care AG Co. KGaA with effect from December 2019, a position he has held since January 1, 2010. He plans to retire from the Company after his successor was identified and transitioned into the role, which is expected by the Company by the end of 2019. Previously, he served as Chief Financial Officer of Fresenius Medical Care North America for seven years. He joined the Company in 1998 as vice president of Finance and Administration for Spectra Renal Management, the companys laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America. Prior to that, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG. He has acted as Member of the Management Board of Fresenius Medical Care Holdings, Inc., U. S. and Member of the Board of Administration of Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland. since 2010.
Age | 63 |
Tenure | 14 years |
Phone | 49 6172 608 2522 |
Web | https://www.freseniusmedicalcare.com |
Fresenius Medical Management Efficiency
The company has return on total asset (ROA) of 0.0253 % which means that it generated a profit of $0.0253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0666 %, meaning that it generated $0.0666 on every $100 dollars invested by stockholders. Fresenius Medical's management efficiency ratios could be used to measure how well Fresenius Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 4 records | CFO Age | ||
Suzanne Snapper | The Ensign Group | 50 | |
Yaw Yap | Concord Medical Services | 56 | |
David Duckworth | Acadia Healthcare | 44 | |
Michael Malatesta | Select Medical Holdings | 54 |
Management Performance
Return On Equity | 0.0666 | |||
Return On Asset | 0.0253 |
Fresenius Medical Care Leadership Team
Elected by the shareholders, the Fresenius Medical's board of directors comprises two types of representatives: Fresenius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius Medical's management team and ensure that shareholders' interests are well served. Fresenius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oliver Maier, Senior Vice President of Investor Relations | ||
Roberto Fuste, Member of the Management Board for Asia-Pacific | ||
Walter Weisman, Member of the Supervisory Board | ||
Michael Brosnan, CFO of Fresenius Medical Care Management AG and Member of the Management Board - Fresenius Medical Care Management AG | ||
Pascale Witz, Member of the Supervisory Board | ||
Katarzyna MazurHofsab, Management AG | ||
Borries Muller, VP Communications | ||
Kent Wanzek, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Global Manufacturing and Quality - Fresenius Medical Care Management AG | ||
Joachim Weith, Sr Affairs | ||
Deborah McWhinney, Member of the Supervisory Board | ||
Robert Powell, Chairman Board | ||
Franklin FACP, Global AG | ||
Dieter Schenk, Vice Chairman of the Supervisory Board | ||
Katarzyna MazurHofsaess, Member of the Management Board | ||
Ronald Kuerbitz, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Fresenius Medical Care North America - Fresenius Medical Care Management AG | ||
Dominik Wehner, Member of the Management Board for Europe, Middle East and Africa | ||
Gregor Zuend, Member of the Supervisory Board | ||
Rolf Classon, Member of the Supervisory Board | ||
Helen Giza, Chief CEO | ||
Ben Lipps, Honorary Chairman | ||
Gregor Zund, Member of the Supervisory Board | ||
Bernd Fahrholz, Member of the Supervisory Board | ||
Nwamaka MD, Head Operations | ||
William Johnston, Member of the Supervisory Board | ||
Olaf Schermeier, Member of the Management Board for Global Research & Development | ||
Dominik Heger, Head of Investor Relations & Corporate Communications | ||
Frank Maddux, Chief Medical Officer | ||
William Valle, CEO for North America, Member of the Management Board | ||
Rice Powell, Chairman of the Management Board, CEO | ||
Harry Wit, Member of the Management Board, CEO for Asia-Pacific | ||
Carla Kriwet, CEO Care | ||
Gerd Krick, Chairman of the Supervisory Board |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fresenius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0666 | |||
Return On Asset | 0.0253 | |||
Profit Margin | 0.04 % | |||
Operating Margin | 0.08 % | |||
Current Valuation | 22.64 B | |||
Shares Outstanding | 293.41 M | |||
Shares Owned By Insiders | 32.16 % | |||
Shares Owned By Institutions | 38.34 % | |||
Price To Earning | 11.60 X | |||
Price To Book | 0.58 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Fresenius Pink Sheet analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |